Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pacira Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
PCRX
Nasdaq
2834
https://www.pacira.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pacira Biosciences Inc
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend
- Apr 11th, 2024 12:37 pm
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
- Apr 4th, 2024 3:33 pm
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Apr 2nd, 2024 12:00 pm
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
- Mar 14th, 2024 12:23 pm
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
- Mar 13th, 2024 11:00 am
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)
- Mar 9th, 2024 4:55 am
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
- Mar 6th, 2024 1:00 pm
11 Best Small Cap Pharma Stocks to Invest In
- Mar 5th, 2024 1:28 am
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 1:38 pm
Pacira BioSciences Full Year 2023 Earnings: EPS Beats Expectations
- Mar 1st, 2024 1:13 pm
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
- Mar 1st, 2024 11:05 am
Q4 2023 Pacira Biosciences Inc Earnings Call
- Mar 1st, 2024 5:28 am
Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023
- Feb 29th, 2024 1:32 pm
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
- Feb 29th, 2024 1:00 pm
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
- Feb 22nd, 2024 1:00 pm
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
- Feb 15th, 2024 1:36 pm
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
- Feb 7th, 2024 1:00 pm
G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams
- Feb 1st, 2024 3:45 pm
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
- Jan 5th, 2024 5:21 pm
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
- Jan 4th, 2024 10:00 pm
Scroll